Targeting Epigenetic Reader and Eraser: Rational Design, Synthesis and in Vitro Evaluation of Dimethylisoxazoles Derivatives As BRD4/HDAC Dual Inhibitors

Zhimin Zhang,Shaohua Hou,Hongli Chen,Ting Ran,Fei Jiang,Yuanyuan Bian,Dewei Zhang,Yanle Zhi,Lu Wang,Li Zhang,Hongmei Li,Yanmin Zhang,Weifang Tang,Tao Lu,Yadong Chen

DOI: https://doi.org/10.1016/j.bmcl.2016.04.034

IF: 2.94

2016-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:The bromodomain protein module and histone deacetylase (HDAC), which recognize and remove acetylated lysine, respectively, have emerged as important epigenetic therapeutic targets in cancer treatments. Herein we presented a novel design approach for cancer drug development by combination of bromodomain and HDAC inhibitory activity in one molecule. The designed compounds were synthesized which showed inhibitory activity against bromodomain 4 and HDAC1. The representative dual bromodomain/HDAC inhibitors, compound 11 and 12, showed potent antiproliferative activities against human leukaemia cell line K562 and MV4-11 in cellular assays. This work may lay the foundation for developing dual bromodomain/HDAC inhibitors as potential anticancer therapeutics.